Wegovy Side Effects: Labels, Warnings and What Users Report
Wegovy side effects: semaglutide label warnings for weight management, serious risks, and what anonymous users report. Small sample. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Wegovy is a semaglutide brand approved for chronic weight management (and, in the US, certain cardiovascular-risk indications). It shares the same active ingredient class as Ozempic, so gastrointestinal side effects — nausea, vomiting, diarrhoea, constipation, abdominal pain — dominate labelling and community stories. Serious label risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycaemia with some diabetes drugs, diabetic retinopathy complications, and a boxed warning about thyroid C-cell tumours in rodents. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Wegovy vs Ozempic side effects
Same molecule, different brands and labelled uses. Side-effect class risks overlap. Brand comparison: Wegovy vs Ozempic. Diabetes-brand twin page: Ozempic side effects.
How often side effects happen in trials
Rounded figures from the STEP 1 trial (68 weeks, adults without diabetes). Most GI effects were mild to moderate and temporary. Last reviewed October 15, 2026.
| Side effect | Wegovy-strength semaglutide | Placebo |
|---|---|---|
| Nausea | About 44% | About 17% |
| Diarrhoea | About 32% | About 16% |
| Vomiting | About 25% | About 7% |
| Constipation | About 23% | About 10% |
| Gallbladder problems (mostly gallstones) | About 3% | About 1% |
| Stopped because of GI side effects | About 5% | Under 1% |
Timing, hair and appearance
GI effects peak during dose escalation and usually ease. Hair loss was reported more often than with placebo in weight trials, generally linked to fast weight loss (hair loss). Facial volume loss is covered on Ozempic face. Wegovy is also approved to lower cardiovascular risk (SELECT trial), so for some people the trade-off includes heart benefit.
When to get medical help
Severe ongoing abdominal pain (possible pancreatitis), upper-right abdominal pain or yellowing skin (gallbladder), signs of dehydration, allergic swelling, a lump in the neck or trouble swallowing, sudden vision changes, or new thoughts of self-harm.
What users report here
Our archive tags semaglutide stories together (37 published confessions in the live report). Counts: semaglutide side-effects report. Facial change and shedding nicknames: Ozempic face, Ozempic hair loss.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- How long do Wegovy side effects last?
- GI effects are most common while the dose is being increased and usually ease afterwards. Persistent vomiting or pain needs a prescriber's review.
- Does Wegovy cause hair loss?
- Hair loss was reported more often than with placebo in weight-management trials, usually linked to rapid weight loss and usually temporary.
- What are the most common Wegovy side effects?
- Labels list gastrointestinal effects as the most common: nausea, diarrhoea, vomiting, constipation and abdominal pain.
- Are Wegovy and Ozempic side effects the same?
- They share semaglutide, so the side-effect class overlaps. Pens, strengths and labelled uses differ.
- How many user reports is this based on?
- Our semaglutide side-effects report uses 37 published anonymous confessions — a small, self-selected sample of phrase matches, not clinical rates.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
- STEP 1 — Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021
- SELECT — Lincoff et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023
- Wegovy (semaglutide) prescribing information — DailyMed (NLM)
- Ozempic (semaglutide) prescribing information — DailyMed (NLM)
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.